Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by KayakerBCon Jul 27, 2017 4:35pm
97 Views
Post# 26518571

Just for a laugh....

Just for a laugh....This is digitroll last month.....

....What is the financing risk to human data given current cash, the apparent ramp-up of spending in general, the cost of the cell line, cost of the non-human primate imaging studies, the timeline to human data, and costs of the Phase 0 trial? Is there a risk of 25% more dilution, for example?

What is the risk the cell line will not be developed on the timeline expected?

What is the risk regulators will want more data before human testing can begin? 

Do we even know what we are waiting two years for without disclosure of the Phase 0 trial design? How meaningful will the Phase 0 data actually be?

How much faith can we put in the lead program given how BTI appears to have dragged its feet concerning human testing, the celll line, not pursued non-human primate testing for it, and given the failure to sign a licensing deals leading to the recent dilution, etc.?....


 

Bullboard Posts